or Try an Advanced Search...

    Technical Analysis for ATHA - Athira Pharma, Inc.

    Grade Last Price % Change Price Change
    B 2.51 -5.28% -0.14
    ATHA closed down 5.28 percent on Monday, July 1, 2024, on 32 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    Earnings due: Jul 18
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical ATHA trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Overbought Stochastic Strength 0.00%
    MACD Bullish Centerline Cross Bullish -5.28%
    MACD Bullish Signal Line Cross Bullish -5.28%
    Doji - Bearish? Reversal -5.28%
    Stochastic Reached Overbought Strength -5.28%
    Overbought Stochastic Strength -5.28%
    Up 3 Days in a Row Strength -5.28%
    Crossed Above 20 DMA Bullish -4.92%
    Lower Bollinger Band Walk Weakness -4.92%
    Older End-of-Day Signals for ATHA ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 10 hours ago
    Down 1% about 10 hours ago
    Rose Above Previous Day's High 3 days ago
    Down 3% 3 days ago
    Down 2 % 3 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ATHA Chart by TradingView
    Basic chart:

    Profile

    Athira, headquartered in Seattle, is a drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is currently advancing its lead therapeutic candidate, NDX-1017, a novel small molecule therapeutic, in later-stage clinical trials for Alzheimer’s.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Drug Development Nasdaq 100 Index Innovative Therapies Brain Disorders

    Is ATHA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 12 Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
    Jun 11 Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
    Jun 3 We're A Little Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate
    May 15 Athira Pharma GAAP EPS of -$0.69
    May 15 Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
    May 2 Athira Pharma to Participate in Upcoming May Conferences
    Apr 23 One Athira Pharma Insider Raised Their Stake In The Previous Year
    Apr 11 Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
    Apr 3 Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
    Mar 29 Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?
    See more ATHA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.2984
    52 Week Low 1.33
    Average Volume 143,472
    200-Day Moving Average 2.40
    50-Day Moving Average 2.36
    20-Day Moving Average 2.50
    10-Day Moving Average 2.46
    Average True Range 0.17
    RSI (14) 51.46
    ADX 21.12
    +DI 24.06
    -DI 23.43
    Chandelier Exit (Long, 3 ATRs) 2.19
    Chandelier Exit (Short, 3 ATRs) 2.63
    Upper Bollinger Bands 2.74
    Lower Bollinger Band 2.26
    Percent B (%b) 0.52
    BandWidth 19.15
    MACD Line 0.01
    MACD Signal Line 0.01
    MACD Histogram 0.0011
    Fundamentals Value
    Market Cap 95.52 Million
    Num Shares 38.1 Million
    EPS -3.17
    Price-to-Earnings (P/E) Ratio -0.79
    Price-to-Sales 0.00
    Price-to-Book 0.82
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.74
    Resistance 3 (R3) 2.75 2.70 2.70
    Resistance 2 (R2) 2.70 2.64 2.69 2.68
    Resistance 1 (R1) 2.60 2.60 2.58 2.59 2.67
    Pivot Point 2.55 2.55 2.53 2.54 2.55
    Support 1 (S1) 2.45 2.49 2.43 2.44 2.35
    Support 2 (S2) 2.40 2.45 2.39 2.34
    Support 3 (S3) 2.30 2.40 2.32
    Support 4 (S4) 2.29